DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DEPOCYT

Summary for Tradename: DEPOCYT

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 DEPOCYT

Pharmacology for Tradename: DEPOCYT

Clinical Trials for: DEPOCYT

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Status: Terminated Condition: Neoplastic Meningitis

Depocyt® With Sorafenib in Neoplastic Meningitis
Status: Terminated Condition: Neoplastic Meningitis

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Status: Terminated Condition: Glioblastoma Multiforme; Glioma; Astrocytoma; Brain Tumor

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Status: Suspended Condition: Acute Lymphoblastic Leukemia

High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer
Status: Recruiting Condition: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain

DepoCyt for Active Lymphomatous or Leukemic Meningitis
Status: Terminated Condition: Neoplastic Meningitis; Lymphoma, B Cell

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Status: Recruiting Condition: Acute Lymphocytic Leukemia; Adult Lymphoblastic Lymphoma

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
Status: Completed Condition: Meningeal Neoplasms

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Recruiting Condition: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); de Novo Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia

Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
Status: Active, not recruiting Condition: Adult Acute Lymphocytic Leukemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc
DEPOCYT
cytarabine
INJECTABLE, LIPOSOMAL;INJECTION021041Apr 1, 1999RXYes5,723,147<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc